Absolutely. All OPT have to do is increase the sample size and these results will reach statistical significance.
Let's not forget how well OPT did to show these results to the market just before COVID caused a major disruption to clinic visits.
Seriously. Results like the ones they reported yesterday don't happen by accident, or as a statistical anomaly. If they give another 100 patients a monthly injection for 3 months, I reckon that's all that would be required to achieve statistical significance.
If you have a look at the clinical trial on clinicaltrials.org, it looks like the study is set to be finalised in August 2020.
PS: if you're not an ophthalmologist, you're doing well. You have a solid understanding of this trial
explain the market cap, page-39
-
- There are more pages in this discussion • 96 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
90.5¢ |
Change
-0.010(1.09%) |
Mkt cap ! $1.114B | |||
| Open | High | Low | Value | Volume |
| 91.5¢ | 91.8¢ | 89.5¢ | $1.036M | 1.140M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 31954 | 89.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 91.5¢ | 71302 | 3 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |